Skip to main content
. 2018 Oct 5;36(33):3324–3330. doi: 10.1200/JCO.18.00454

Fig 3.

Fig 3.

(A) Overall survival (OS) for adjuvant gemcitabine plus docetaxel followed by doxorubicin versus observation in GOG 0277. (B) Recurrence-free survival (RFS) for gemcitabine-docetaxel followed by doxorubicin versus observation in GOG 0277. Doc, docetaxel; Dox, doxorubicin; Gem, gemcitabine.